Biotech Kyverna surges 36 percent in US debut
Bringing Taiwan to the World and the World to Taiwan
Source: taipeitimes.com
📰 Peter Maag News
Page 2 - Peter Maag News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Maag. Real-time updates on events, politics, business and more.
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...
United States Peter Maag Prnewswire Kyverna Therapeutics Inc National Institutes Of Health Drug Administration Northern European
Source: prnewswire.com
FDA Grants Fast Track Status to Anti-CD19 CAR T-Cell Therapy for MS
The FDA has granted Fast Track designation to KYV-101 for the treatment of refractory, progressive multiple sclerosis.
Source: empr.com
KYV-101 Multiple Sclerosis Treatment Gets FDA Clearance - Physical Therapy Products
A study will seek to answer whether CAR T-cell therapy using KYV-101 offers a new treatment option for patients living with MS.
Source: ptproductsonline.com
Kyverna Therapeutics' IND application for MS therapy receives clearance
Kyverna Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for KYV-101
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...
United States Christian Pflaumer Peter Maag National Institutes Of Health Kyverna Therapeutics Inc Drug Administration
Source: prnewswire.com
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it...
United States Peter Maag Christian Pflaumer Kyverna Therapeutics Inc Drug Administration National Institutes Of Health
Source: lelezard.com
Kyverna's CAR T-Cell Therapy Expands Autoimmune Investigations Into Myasthenia Gravis
The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.
Source: ajmc.com
Haivision, Grabyo Launch Fully Integrated Solution for Live Multi-Camera Cloud Production
The offering uses Haivision’s video contribution solutions to stream synchronized ultra-low latency video to the Grabyo cloud production platform
Source: tvtechnology.com